drugset / Trial / NCT06363552
A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer
RandomizedParallel-groupSingle-blindTreatment
Summary
The goal of this clinical trial is to evaluate the preliminary safety and efficacy of SC0191 as single agent or in combination with bevacizumab or 5-FU/LV in advanced colorectal cancer.
Timeline
- Start
- 2024-05
- Primary completion
- 2025-04
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Calcium folinate | Unknown | 400 mg/m2 | Intravenous |
| Subject | SC0191 | Small molecule | 300 mg | Oral |
| Subject | fluorouracil | Small molecule | 1200 mg/m2 | Intravenous |